RRM2 and frontotemporal dementia: By generating a panel of monoclonal antibodies, we identified several clones directed against the RRM2 and the glycine-rich domain that potently inhibited TDP-43 aggregation and phase separation in vitro, events tightly linked to neurodegeneration in ALS/FTD [3, 36].